Novel anti-inflammatory functions for endothelial and myeloid cyclooxygenase-2 in a new mouse model of Crohn's disease

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 298, Issue 6, 2010, Pages

  Watanabe, Junji ^a   Lin, James A ^a   Narasimha, Ajay J ^b   Shahbazian, Ani ^a   Ishikawa, Tomo O ^b   Martin, Martin G ^a   Herschman, Harvey R ^b   Reddy, Srinivasa T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ileo ceco colic junction; Inflammation

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; ENDOTHELIAL CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 6; MYELOID CYCLOOXYGENASE 2; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; CELL INFILTRATION; CONTROLLED STUDY; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; FLOW MEASUREMENT; GRANULOCYTE; HISTOPATHOLOGY; LIPID DIET; MACROPHAGE; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE;

ANIMALS; CAENORHABDITIS ELEGANS PROTEINS; CECUM; CHOLATES; COLON, ASCENDING; CROHN DISEASE; CYCLOOXYGENASE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; ILEUM; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; TRANSCRIPTION FACTORS;

EID: 77952713742     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00468.2009     Document Type: Article

References (59)

1. Alva JA, Zovein AC, Monvoisin A, Murphy T, Salazar A, Harvey NL, Carmeliet P, Iruela-Arispe ML. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn 235: 759-767, 2006.
2. Barrera S, Lai J, Fiocchi C, Roche JK. Regulation by prostaglandin E2 of interleukin release by T lymphocytes in mucosa. J Cell Physiol 166: 130-137, 1996. (Pubitemid 3017110)
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 2000.
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005. (Pubitemid 40365350)
5. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735-741, 1999. (Pubitemid 29191226)
6. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 46: 1-6, 2002. (Pubitemid 35300786)
7. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8: 265-277, 1999. (Pubitemid 29523965)
8. Colpaert S, Vanstraelen K, Liu Z, Penninckx F, Geboes K, Rutgeerts P, Ceuppens J. Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Clin Immunol 102: 68-76, 2002. (Pubitemid 34095226)
9. Correa I, Veny M, Esteller M, Pique JM, Yague J, Panes J, Salas A. Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol 85: 896-903, 2009.
10. de Villiers WJ. Crohn's disease and IL-10 therapy: promise regained. Inflamm Bowel Dis 9: 210-211, 2003.
11. Diaz G, Melis M, Batetta B, Angius F, Falchi AM. Hydrophobic characterization of intracellular lipids in situ by Nile Red red/yellow emission ratio. Micron 39: 819-824, 2008.
12. Doroudi R, Gan LM, Selin Sjogren L, Jern S. Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biomechanical perfusion model. Biochem Biophys Res Commun 269: 257-264, 2000. (Pubitemid 30440287)
13. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675-684, 2004. (Pubitemid 39140623)
14. Fiorucci S, de Lima OM Jr, Mencarelli A, Palazzetti B, Distrutti E, McKnight W, Dicay M, Ma L, Romano M, Morelli A, Wallace JL. Cyclooxygenase-2- derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123: 1598-1606, 2002. (Pubitemid 35231659)
15. Greenspan P, Mayer EP, Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol 100: 965-973, 1985. (Pubitemid 15135357)
16. Hatazawa R, Tanaka A, Tanigami M, Amagase K, Kato S, Ashida Y, Takeuchi K. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol Gastrointest Liver Physiol 293: G788-G797, 2007. (Pubitemid 47605917)
17. Hori M, Kita M, Torihashi S, Miyamoto S, Won KJ, Sato K, Ozaki H, Karaki H. Upregulation of iNOS by COX-2 in muscularis resident macrophage of rat intestine stimulated with LPS. Am J Physiol Gastrointest Liver Physiol 280: G930-G938, 2001. (Pubitemid 32436031)
18. Ikenoue Y, Tagami T, Murata M. Development and validation of a novel IL-10 deficient cell transfer model for colitis. Int Immunopharmacol 5: 993-1006, 2005. (Pubitemid 40501744)
19. Ishikawa TO, Herschman HR. Conditional knockout mouse for tissuespecific disruption of the cyclooxygenase-2 (Cox-2) gene. Genesis 44: 143-149, 2006.
20. Jennings-Peterson D, Wolfe S. Petition to remove the Cox-2 Inhibitors Celecoxib (CELEBREX) and Valdecoxib (BEXTRA) From the Market (HRG Publication #1720), 2005.
21. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423, 1999.
22. Lin JA, Watanabe J, Rozengurt N, Narasimha A, Martin MG, Wang J, Braun J, Langenbach R, Reddy ST. Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice. Prostaglandins Other Lipid Mediat 84: 98-107, 2007. (Pubitemid 350030576)
23. Lusis AJ, Yu J, Wang SS. The problem of passenger genes in transgenic mice. Arterioscler Thromb Vasc Biol 27: 2100-2103, 2007. (Pubitemid 350287236)
24. Madsen K. Combining T cells and IL-10: a new therapy for Crohn's disease? Gastroenterology 123: 2140-2144, 2002. (Pubitemid 35408335)
25. Madsen KL. Inflammatory bowel disease: lessons from the IL-10 genedeficient mouse. Clin Invest Med 24: 250-257, 2001.
26. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97: 910-914, 2002.
27. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277, 1999. (Pubitemid 29036089)
28. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633-1644, 2006. (Pubitemid 44511610)
29. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112: 387-397, 1997. (Pubitemid 27078825)
30. Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 11: 323-344, 1977. (Pubitemid 8197170)
31. Monteleone G, Parrello T, Monteleone I, Tammaro S, Luzza F, Pallone F. Interferon-gamma (IFN-gamma) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC). Clin Exp Immunol 117: 469-475, 1999. (Pubitemid 29398292)
32. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959, 2001. (Pubitemid 33010342)
33. Narasimha AJ, Watanabe J, Ishikawa T, Priceman SJ, Wu L, Herschman HR, Reddy ST. Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein e null mice. Arterioscler Thromb Vasc Biol 30: 260-268, 2010.
34. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 49: 6-8, 1997.
35. Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 5: 900-906, 1999.
36. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091, 2005. (Pubitemid 40365349)
37. Okahara K, Sun B, Kambayashi J. Upregulation of prostacyclin synthesis- related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 18: 1922-1926, 1998.
38. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125: 1481-1492, 2003. (Pubitemid 36759251)
39. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48: 623-631, 1997. (Pubitemid 28055590)
40. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 299: 1813-1817, 2008.
41. Romero M, Artigiani R, Costa H, Oshima CT, Miszputen S, Franco M. Evaluation of the immunoexpression of COX-1, COX-2 and p53 in Crohn's disease. Arq Gastroenterol 45: 295-300, 2008.
42. Saam JR, Gordon JI. Inducible gene knockouts in the small intestinal and colonic epithelium. J Biol Chem 274: 38071-38082, 1999.
43. Sato K, Torihashi S, Hori M, Nasu T, Ozaki H. Phagocytotic activation of muscularis resident macrophages inhibits smooth muscle contraction in rat ileum. J Vet Med Sci 69: 1053-1060, 2007. (Pubitemid 350126351)
44. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115: 297-306, 1998. (Pubitemid 28363422)
45. Singh UP, Singh S, Taub DD, Lillard JW Jr. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 171: 1401-1406, 2003. (Pubitemid 36900073)
46. Smythe EM, Burke A, FitzGerald GA. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, edited by Brunton LL, Lazo JS, Parker KL. New York: McGraw-Hill, 2005, p. 653-670.
47. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028-1035, 2006. (Pubitemid 44358879)
48. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104-2113, 2008. (Pubitemid 351572169)
49. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93: 10417-10422, 1996.
50. Ukawa H, Yamakuni H, Kato S, Takeuchi K. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig Dis Sci 43: 2003-2011, 1998.
51. Van der Heijden PJ, Stok W. Improved procedure for the isolation of functionally active lymphoid cells from the murine intestine. J Immunol Methods 103: 161-167, 1987.
52. Vane JR, Botting RM. New insights into the mode of action of antiinflammatory drugs. Inflamm Res 44: 1-10, 1995.
53. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, Fogelman AM, Reddy ST. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 284: 18292-18301, 2009.
54. Wei B, Velazquez P, Turovskaya O, Spricher K, Aranda R, Kronenberg M, Birnbaumer L, Braun J. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci USA 102: 2010-2015, 2005.
55. Weigmann B, Tubbe I, Seidel D, Nicolaev A, Becker C, Neurath MF. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc 2: 2307-2311, 2007.
56. Ye J, Lee JW, Presley LL, Bent E, Wei B, Braun J, Schiller NL, Straus DS, Borneman J. Bacteria and bacterial rRNA genes associated with the development of colitis in IL-10(-/-) mice. Inflamm Bowel Dis 14: 1041-1050, 2008.
57. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20: 445-451, 1999. (Pubitemid 29112633)
58. Zhang R, Li Y, Beck PL, McCafferty DM. Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-)) mice. Biochem Soc Trans 35: 1375-1376, 2007. (Pubitemid 350206504)
59. Zhang Z, Sheng H, Shao J, Beauchamp RD, DuBois RN. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia 2: 523-530, 2000. (Pubitemid 32098687)